A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Summary

This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).

Timeline

Start

2016-10-18

Primary completion

2018-04-20

Completion

2018-04-20

Drugs

Indications